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Abstract
In this paper we develop a new mathematical model of immunotherapy and cancer vaccination,
focusing on the role of antigen presentation and costimulatory signaling pathways in cancer immunology.
We investigate the effect of different cancer vaccination protocols on the well-documented phenomena of
cancer dormancy and recurrence, and we provide a possible explanation of why adoptive immunotherapy
protocols can sometimes promote tumor growth instead of inhibiting it (a phenomenon called immunostimulation), as opposed to active vaccination protocols based on tumor-antigen pulsed dendritic cells.
Significantly, our simulations suggest that elevated numbers of professional antigen presenting cells
correlate well with prolonged time periods of cancer dormancy.
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Introduction

over the past few decades with refinement of anticancer drugs and medical equipment, unfortunately
chemotherapy and radiotherapy both still carry major side-effects for individual patients. This is mainly
due to the severe effects that these treatments have
on normal, healthy proliferating cells in the patients.
As a result, the treatment of cancers itself causes significant morbidity and mortality.

Cancer still remains one of the most difficult diseases
to treat clinically and is one of the main causes of
mortality in developed western societies. The mortality statistics for the United Kingdom for the year
2005 show that 153,491 people were registered as
dying from a malignant neoplasm.1 This figure represents 26% of all causes of death in the UK for 2005,
and similar statistics hold for the United States (Ries
et al., 2007).
Great effort and resources are devoted to cancer
research and our understanding of cancer biology
is constantly expanding. However, the overall efficiency of our current therapeutic approaches remains rather poor. Current patient therapies for
the treatment of cancer include surgery (i.e. removal of the tumour), chemotherapy (administration of anti-cancer drugs) and radiotherapy (treatment with X-rays). Of course surgery is appropriate only for solid tumours. Although there have
been great advances in patient care and treatment
∗
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Given these facts any design of new therapeutic
approaches is of great interest and one such new approach is to treat cancer using key components of the
immune system, the body’s natural defence mechanism (Abbas et al., 2007). In recent years there
has been much biological, immunological and experimental interest in trying to develop what may be
termed “immunotherapies” for cancers. One major
advantage that some form of effective immunotherapy treatment would have over conventional anticancer treatment would be the fact that cells and
other components of the immune system would be
far more specific and localised in their actions, targetting cancer cells alone and leaving the vast majority of other healthy cells of the body untouched
(Parmiani & Lotze, 2002).

E-mail address: tasos@math.ohio-state.edu
Source: Cancer Research UK
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As part of a deeper understanding of cancer therapy the role of quantitative and predictive mathematical modelling is becoming increasingly appreciated by experimentalists and clinicians, and in
recent years several papers have begun to investigate the various aspects of the immune system response to cancer from a mathematical perspective.
The development of mathematical models which reflect several spatial and temporal aspects of tumour
immunology can be regarded as the first step towards an effective computational approach in investigating the conditions under which tumour recurrence takes place and in optimizing existing immunotherapy protocols. Key papers in this area include (Ambrosi et al., 2002; Arlotti et al., 2002; De
Angelis et al., 2003; Bellomo et al., 2003; Bellomo
et al., 1999; Bellomo & Preziosi, 2000), which focus on the modelling of tumour progression and
immune competition by generalized kinetic (Boltzmann) models and (Owen & Sherratt, 1997; Owen
& Sherratt, 1998; Owen & Sherratt, 1999; Sherratt
et al., 1999), which focus on the development of tumour heterogeneities as a result of tumour cell and
macrophage interactions. Moreover, Webb et al.
(2002) is concerned with receptor-ligand (Fas-FasL)
dynamics, Kelly et al. (2002) investigate the process
of macrophage infiltration into avascular tumours,
Matzavinos et al. (2004), Matzavinos & Chaplain
(2004) and Chaplain & Matzavinos (2006) focus on
the dynamics of cytotoxic T cell-tumour cell interactions, and finally Foryś (2002) and Szymańska (2003)
analyze various immune system and immunotherapy
models in the context of cancer dynamics.
In this paper we develop a new mathematical
model of immunotherapy, focusing on the role of
antigen presentation and costimulatory signaling
pathways in cancer immunology. We investigate
the effect of different cancer vaccination protocols
on the well-documented phenomena of cancer dormancy and recurrence, and we provide a possible
explanation of why adoptive immunotherapy protocols can sometimes promote tumor growth instead
of inhibiting it2 (Zhang et al., 2007), as opposed to
active vaccination protocols based on tumor-antigen
pulsed dendritic cells (Banchereau & Palucka, 2005).

2
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The Mathematical Model
Model formulation

Let us consider a simplified process of a small, growing, avascular tumour which elicits a response from
the host immune system and attracts a population
of lymphocytes and antigen presenting cells (APCs).
The growing tumour is directly attacked by cytotoxic T-lymphocytes (CTLs), which in the presence
of tumour antigens undergo enhanced proliferation.
Antigen presenting cells, such as dendritic cells or
macrophages, internalize tumour cells through either
phagocytosis or endocytosis, and display selected tumour antigenic peptides to the effector cells, i.e. the
CTLs. In the following we only consider the class
I MHC pathway of antigen presentation (Abbas et
al., 2007), where the antigenic peptides are presented
to and activate CTLs directly (as opposed to the
class II MHC pathway that converges to the activation of helper T-cells that, in turn, activate the
effector components of the host immune system).
The role of antigen presenting cells in the model
is three-fold: (a) they internalize tumour cells and
present tumour antigens to the effector cells, (b) they
kill the internalized tumour cells through the action
of proteolytic enzymes, and (c) they are subjected to
programmed cell death as a result of their presenting of antigenic peptides to CTLs. The main effector functions of this system are performed by CTLs,
which detect antigenic peptides either directly on tumour cells or through the presentation mechanism
implemented by antigen presenting cells. Upon antigen recognition, CTLs bind to the target cell (which
can be either a tumour cell or an antigen presenting
cell with an internalized tumour cell). This binding
event leads to the clustering of a large number of
CTL receptors, trigerring a cascade of events that
converge to the delivery of an apoptotic signal and
the killing of the target cell.
The kinetic interactions between the various cell
types of the model are described by the kinetic
scheme given in Fig. 1. The model consists of
ten time-dependent variables representing the total
numbers of effector cells E, tumour cells T , naive
antigen presenting cells A, tumour cell-loaded APCs
2
A phenomenon that is usually referred to as immunostim- L, CTL-tumour cell complexes CT , CTL-APC complexes CA , CTL-CTL complexes CE , inactivated
ulation.
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gagement of Fas on a target cell by FasL triggers a
cascade of cellular events that result in programmedcell-death. Both these transmembrane proteins (belonging to the tumour necrosis factor (TNF) family of receptors and ligands) are expressed on the
surface of immune cells, including T-lymphocytes
and NK-cells. However, many non-lymphoid tumour cells also express FasL which can counterattack and kill the Fas-sensitive CTLs. On the other
hand, most cancer cells, unlike normal cells, are relatively resistent to Fas-mediated apoptosis by the
immune cells. Resistance to programmed-cell-death
(apoptosis) through the Fas receptor pathway coupled with expression of the Fas ligand might enable many cancer cells to deliver a “counterattack”
against attached cytotoxic lymphocytes.
In the formulation of the model, and in addition to
Figure 1: Schematic diagram of the interactions bethe kinetic mechanisms described in Fig. 1, we contween effector cells (CTLs), tumour cells and antigen
sider other kinetic interaction terms accounting for
presenting cells.
the host immune system homeostasis, the enhanced
proliferation of lymphocytes in the presence of antie lethally-hit (or programmed-for-lysis) tu- gen, etc.
CTLs E,
mour cells Te and programmed-for-lysis loaded APCs
e
L.
Cytotoxic T-lymphocytes
±
The parameters kT± , kCT , kA , kL , kL± , kCA , kE
and
kCE are non-negative kinetic constants. Parameters We assume that there is a source term modelling
kT+ and kT− describe the rate of binding of CTLs to the underlying lymphocyte production by the host
tumour cells and detachment of CTLs from tumour immune system, a linear decay (death) term and an
cells without damaging cells; kCT is the rate of de- additional CTL proliferation term in response to the
tachment of CTLs from tumour cells, resulting in an presence of the tumour cells. Combining these asirreversible programming of the tumour cells for lysis sumptions with the kinetics derived from Fig. 1 we
(i.e. death) with probability p or inactivating/killing have the following ordinary differential equation for
± CTLs:
CTLs with probability (1 − p). Similarly, kL± and kE
are the corresponding kinetic constants for binding
proliferation
z
}|
{
linear decay
and detachment of CTLs to tumour cell-loaded antisupply
z}|{
z}|{
f
(C
+
C
)
dE
T
A
gen presenting cells and other CTLs without dam=
s1 − d1 E +
dt
g+T
aging cells. Parameters kC and kC are the rate
A

E

mass action kinetics, according to Fig. 1
constants for the CTL-mediated killing of (a) loaded
z
}|
{
antigen presenting cells and (b) CTLs respectively,
− kT+ ET + (kT− + kCT p)CT − kL+ LE
whereas kA and kL characterize the rate of tumour
mass action kinetics
z
}|
{
cell internalization by antigen presenting cells and
−
+ kL− CA + kCA CA + 2kE
CE
the destruction/lysis of internalized tumour cells.
Fas/FasL interactions
The kinetic step that corresponds to the constant
}|
{
z
+ 2
kCT (1−p) models a direct “counterattack” of the tu(1)
− 2kE E + kCE CE ,
mour cells against effector immune cells. O’Connell
±
et al. (1999) have shown that such a mechanism where s1 , d1 , f , g, kE
, kT± , kL± , kCE , kCT , kCA are
might be realized through the Fas receptor (Fas, all positive constants. The parameter s1 represents
Apo-1/CD95) and its ligand (FasL, CD95L). En- the ‘normal’ rate of flow of mature lymphocytes into
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the tissue (non-enhanced by the presence of tumour
cells).
The proliferation term f (CT + CA )/(g + T ) represents the experimentally observed enhanced proliferation of CTLs in response to the tumour. Similar functional forms for this term have been derived
through data fitting and used by Kuznetsov et al.
(1994), Chaplain et al. (1998) and Matzavinos et
al. (2004). This functional form is also consistent
with a model in which one assumes that the enhanced proliferation of CTLs is due to signals, such
as released interleukins, generated by effector cells
in target cell-CTL complexes (where a target cell
is either a tumour cell or a antigen presenting cell
with an internalized tumour cell). We note that the
growth factors that are secreted by lymphocytes in
complexes (e.g. IL-2) act mainly in an autocrine
fashion. That is to say they act on the cell from
which they have been secreted. We assume that the
growth factors are produced when lymphocytes are
activated by target cell-CTL interactions. Thus we
define effector cell proliferation to be proportional to
target cell-CTL complex density CT + CA . The kinetic interaction terms related to the rate constants
+
−
kE
, kE
and kCE correspond to Fas/FasL interactions
between effector cells (Marsden & Strasser, 2003).

4

space. This is a reasonable assumption since according to observations (Kyle et al., 1999) the volume
of extracellular space in tumours is typically in the
range 25-65% of the total volume of cells and hence
there is enough space for the migration of lymphocytes within a tumour. Also, tumour cells lack the
contact inhibition properties of normal cells and destroy the extracellular matrix. This allows the lymphocytes to migrate into the tumour tissue faster
than in normal tissue, which has regular extracellular matrix. Therefore we do not explicitly include a
term for space competition between the tumour cells
and the lymphocytes and thus a logistic growth term
is, we believe, a good first modelling approximation
to the tumour growth kinetics.
In the presence of CTLs and antigen presenting
cells, the ODE governing the tumour growth dynamics in conjunction with the interactions dictated by
the kinetic scheme in Fig. 1 is:
mass action kinetics, according to Fig. 1

dT
dt

z
}|
 {
= − kT+ ET + kT− + kCT (1 − p) CT
mass action kinetics

−

z }| {
kA T A

logistic growth

z
}|
{
+ b1 T (1 − b2 T ) (3)

where b1 , b2 , p, kT± , kCT and kA are positive parameters.

Tumour cells
Antigen presenting cells
The growth dynamics of pre-angiogenic tumours, in
the absence of an immune system response, may be The antigen presenting cell population is represented
by two variables, distinguishing between those antidescribed adequately by the logistic equation:
gen presenting cells that are associated with an indT
= b1 T (1 − b2 T ),
(2) ternalized tumour cell and those that are not. The
dt
former population is denoted by L (loaded cell popwhich takes into account a density limitation of ulation), whereas the latter is denoted by A.
As in the case of CTLs, the model incorporates
growth (Prigogine & Lefever, 1980; Durand &
Sutherland, 1984). The maximal growth rate of a source term modelling the underlying cell producthe tumour cell population is b1 , which incorporates tion by the host immune system and a linear decay
both cell multiplication (mitosis) and death, and the (death) term. Combining these processes with the
maximum density of the tumour cells is represented kinetic scheme in Fig. 1, we get the following equation for the non-tumour-bearing population:
by the parameter b−1 .
2

linear decay
mass action kinetics
An alternative approach is to modify the logissupply
z}|{
z
}|
{
z}|{
dA
tic growth kinetics by incorporating terms modelling
=
s2 − d2 A − kA T A + kL L (4)
dt
competition for space between various cell types
(Gatenby, 1995; Gatenby, 1996). However, in the where the parameters s2 and d2 correspond to the
framework of our model, we will assume that the flow of antigen presenting cells into the tissue and
CTLs do not compete with the tumour cells for the decay constant due to cell death respectively.
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Table 1: Estimated kinetic rate constants.
Symbol
g
kT+
d1
s1
kL+
+
kE
s2

Value
2.02 × 107 cells
1.3 × 10−7 day−1 cells−1
0.0412 day−1
1.36 × 104 day−1 cells
1.3 × 10−7 day−1 cells−1
1.3 × 10−7 day−1 cells−1
1.36 × 104 day−1 cells

Symbol
b2
kCT
f
kA
kL−
−
kE
d2

Value
2.0 × 10−9 cells−1
7.2 day−1
0.2988 × 108 day−1 cells
0.5 × 10−6 day−1 cells−1
24 day−1
24 day−1
0.0412 day−1

Symbol
kT−
p
b1
kL
kCA
kCE

Value
24 day−1
0.9997
0.18 day−1
10.0 day−1
7.2 day−1
7.2 day−1

The dynamics of the loaded cell population are (Siu et al., 1986; Uhr & Marches, 2001). It has
governed by the kinetic scheme in Fig. 1, and the been demonstrated that CD8+ T-cells (CTLs) are
corresponding equation for L is:
required for inducing and maintaining dormancy in
BCL1 . In these experiments CD8+ T cells are endL
+
−
= kA T A − kL L − kL LE + kL CA (5) hanced with anti-Id antibodies into inducing dordt
mancy by secreting INF-γ. A description of the
growth kinetics of a BCL1 lymphoma in the spleen
Cell complexes
of recipient mice, chimeric with respect to the Major
The dynamics of cell-complexes are governed by the Histocompatibility Complex (Siu et al., 1986), was
kinetics derived from Fig. 1. Therefore the equa- provided by the model of Matzavinos et al. (2004).
tions for the complexes are given by:
The kinetic constants that correspond to the interactions
of CTLs with tumour cells in the model
dCT
= kT+ ET − (kT− + kCT )CT ,
(6) developed in this paper have been obtained from
dt
Matzavinos et al. (2004). The remaining of the kidCA
= kL+ LE − (kL− + kCA )CA ,
(7) netic constants have been chosen on the basis of
dt
generic order of magnitude estimates. The latter
dCE
+ 2
−
(8) were obtained by comparison of the associated time
= kE
E − (kE
+ kCE )CE .
dt
scales with those corresponding to the fitted kinetic
constants of Matzavinos et al. (2004). Table 1 shows
Cells programmed for lysis
the values of the kinetic constants used in the numerThe time-dependent variables corresponding to the
ical simulations of the following section.
tumour cells and APCs that have been programmed
The system of equations (1)-(8) is closed by apfor lysis are “slave variables” of the system and don’t
plying appropriate initial conditions. The initial cell
provide any feedback to the equations for the other
counts of effector and tumour cells are those used by
cell types. Hence, in the following we focus on the
Matzavinos et al. (2004) and are given by:
system of equations (1)-(8).
1
s1
E0 =
(9)
and T0 = .
d1
b2
2.2 Estimation of parameters
In order to carry out an analysis of the model by
numerical methods it is useful to estimate values for
the parameters obtained from experimental data and
work with a non-dimensionalized system of equations.
The murine B cell lymphoma (BCL1 ) is used as an
experimental model of tumour dormancy in mouse

Under physiological conditions, in the absence of a
tumour and assuming that the Fas/FasL apoptotic
pathway is inactive, the steady-state value of E is
s1 /d1 and therefore this is the value we have taken
for the initial cell count E0 . Similarly, in the absence
of an immune response,the steady-state tumour cell
count is 1/b2 and this is what we take as the initial
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Figure 2: Evolution in time of (non-dimensionalized)
tumour cell counts under different initial numbers
of (a) antigen presenting cells and (b) cytotoxic Tlymphocytes.
tumour cell count T0 . It is assumed that there are no
cell complexes or tumour cell-loaded APCs initially.
Finally, the initial CTL to APC ratio is assumed to
be 1 : 10.3
The closed system has been non-dimensionalized
by choosing order-of-magnitude scales according to
the initial conditions, and the numerical results in
the next section are given in terms of the nondimensionalized system.
3

Estimates of the CTL to APC ratio in the literature vary
from 10 : 1 to 1 : 30 (in tumour infiltrates).

6

Results

The non-dimensionalized system was solved numerically under different experimental settings using the stiff solver of the XPP numerical package
(Ermentrout, 2002). A stiff solver is needed for solving numerically the ODE model developed in this
paper due to the wide range of parameter values in
Table 1.
The main focus of the numerical experiments was:
(a) to investigate the relative importance of CTLs
and antigen presenting cells on tumour dormancy
and tumour recurrence and (b) to quantify the effectiveness of different cancer vaccination protocols.
The vaccination protocols considered were based on
the administration of antigen presenting cell vaccines
(Banchereau & Palucka, 2005), and the effectiveness
of the latter was compared to that of an adoptive
(passive) immunotherapy approach based on the administration of CTLs (Gattinoni et al., 2006). An
excellent review of the current cancer immunotherapy approaches is given by Gilboa (2004).
Figures 2(a) and 2(b) show the results of a computational experiment that quantifies how different
numbers of CTLs and antigen presenting cells affect
the time period between tumour regression and recurrence. All parameter values for these simulations
were set according to Section 2.2. The initial conditions for variables A in Fig. 2(a) and E in Fig. 2(b)
were varied in a biologically-relevant range around
the values adopted in Section 2.2.
For all parameter values investigated, in both Figs.
2(a) and 2(b), the tumour cell population intially
decreases in number before subsequently settling to
some stationary value for a finite period of time. For
visualization purposes, the transient decrease in the
number of tumour cells is not shown. The reduced
tumour bulk attained in the simulations after tumour regression persists until the tumour recurs at
a time that depends on the initial CTL and antigen
presenting cell counts. As shown in Fig. 2(a), the
initial antigen presenting cell count correlates well
with the tumour dormancy period, and the model
suggests that elevated numbers of antigen presenting
cells result in significantly delaying tumour recurrence. These results also suggest a potential role for
antigen presenting cells as biological markers, indicating high-risk time periods for tumour recurrence.

Joshi et al. – On immunotherapies and cancer vaccination protocols

Figure 3: (a) Effect of parameter kCE on the dormancy period and the recurrence of the disease. (b)
Continuation of the non-dimensionalized solution for
variable T with respect to kCE .
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bers of CTLs result not only to tumour cell killing,
but also to CTL killing, enabling tumour cells to
escape cancer dormancy on a faster time scale.
These results offer a possible explanation for
a number of reported failures of CTL vaccinebased therapeutic approaches to certain carcinomas
(see, for example, Zhang et al., 2007). The rationale of such approaches is based on the welldocumented correlation between melanoma patient
survival and tumour infiltrating lymphocyte (TIL)
counts (Weinberg, 2007). However, TIL populations are highly heterogeneous, including among
others CTLs (CD8+ cells), natural killer-like (NKlike) cells and/or lymphokine activated killer (LAK)
cells, with different TIL subpopulations showing different degrees of sensitivity to Fas/FasL mediated
apoptosis. Hence, the reported correlation between
melanoma patient survival and TIL counts does not
contradict the results in this section, since the latter are related to CTLs that are responsive to the
Fas/FasL signalling pathway. Moreover, the dynamics of the model under investigation are consistent
with well-documented tumour recurrence phenomena, following the application of CTL-based vaccination protocols (Zhang et al., 2007).
In addition to observing the effect of different cell
counts on the dormancy period, we also investigated
how the latter is affected by the time scale on which
lymphocytes detect and bind to tumour cells, as well
as by the cytotoxicity of CTLs to each other. Figure 3(a) shows the evolution in time of the tumour
cell population for three different values of the kinetic parameter kCE that measures the rate by which
CTLs inactivate/kill each other through Fas/FasL
interactions. Interestingly enough, reducing parameter kCE leads to early tumour recurrence associated
with a reduced tumour bulk. In contrast, increasing
kCE results in prolonging the dormancy period and
delaying the recurrunce of the disease. However, the
model predicts that increasing kCE also results in an
enlarged tumour bulk after recurrence. Figure 3(b)
shows a continuation of the (non-dimensionalized)
solution for variable T with respect to parameter
kCE .

Figure 2(b) shows an interesting, counter-intuitive
phenomenon. According to the model under investigation, elevated initial numbers of CTLs (as compared to the base value in Section 2.2) result in a
reduced period of cancer dormancy and an early
recurrence of the disease. Moreover, relatively reduced initial numbers of CTLs result in a prolonged
dormancy period. This phenomenon should be attributed to the cytotoxicity of activated lymphocytes
Interesingly enough, reducing parameter kCE beto each other (Fas/FasL interactions). Indeed, initial low the value of 1 day−1 does not result in complete
conditions that are characterized by elevated num- eradication of the tumour mass, as one would ex-
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Figure 4: Emergence of periodic recurrences for small values of parameter kCE
pect by extrapolation of the data in Fig. 3(b). Instead, in this parameter regime, the evolution of the
disease is characterized by periodic recurrences; a
phenomenon that frequently appears in the context
of general immune-pathogen interactions (Wodarz,
2007) and has also been documented in the specific
case of tumour-immune interactions (Kirschner &
Panetta, 1998; Kuznetsov et al., 1994; Matzavinos
& Chaplain, 2004). Figure 4 shows the dependence
of the emerging oscillatory solutions on parameter
kCE . The model predicts that, although the first recurrence of the disease is independent of the value
of kCE , subsequent recurrences will strongly depend
on the sensitivity of the effector cells to Fas/FasL
mediated apoptosis. Numerical continuation of the
system with the XPP implementation of the AUTO
continuation software (Ermentrout, 2002) confirmed
that these oscillatory dynamics emerge through a

Hopf bifurcation with respect to parameter kCE .
Figure 5(a) shows the evolution in time of the tumour cell population for four different values of the
kinetic parameter kT+ , which determines the time
scale of CTL-binding to tumour cells. As can be
seen, elevated values for kT+ result in both a prolonged dormancy period and a reduced tumour bulk
after recurrence of the disease. This result indicates
the importance of identifying immunodominant tumour peptides in the development of cancer vaccines
(Raitakari et al., 2003) and suggests a cellular process, the facilitation of which would enhance the effectiveness of the vaccine.
In addition to vaccine effectiveness, we investigated computationally the effectiveness of different
vaccine administration protocols. Figure 5(b) shows
how the time period elapsed before recurrence of
the disease depends on the number of monthly im-
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Figure 5: (a) Effect of parameter kT+ on the dormancy period and the recurrence of the disease, (b) Plot of
the tumour dormancy time period versus the number of immunizations for two different cancer vaccination
protocols.
munizations under two different vaccination strategies. As can be seen active vaccination with tumourantigen pulsed APCs is associated with a positive
correlation between the number of immunizations
and the tumour dormancy period, and it is generally more effective than adoptive immunotherapy
protocols. In contrast, the adoptive (passive) imnmunotherapy protocol simulated (based on CTL vaccines) fails to mount an effective immune response
even in the case of a significant number of repeated
immunizations.

4

Discussion

In this paper we have developed a mathematical
model to describe the growth dynamics of an immunogenic tumour in the presence of an active immune response. In particular, we focused attention
upon the interaction of tumour cells with CD8+ cytotoxic T-lymphocytes and professional antigen presenting cells in a relatively small, multicellular tumour, without central necrosis and at some stage
prior to tumour-induced angiogenesis (Weinberg,
2007). Following the approach of Matzavinos et al.
(2004) and Matzavinos & Chaplain (2004), the cytotoxic T-lymphocytes were assumed to interact with
the tumour cells in such a way that lymphocyte-

tumour cell complexes were formed. These complexes resulted in either the death of the tumour cells
(the normal situation) or the inactivation (sometimes even the death) of the lymphocytes.
The model developed in this paper extends the
work of Chaplain & Matzavinos (2006) by investigating the role of antigen presentation and costimulatory signaling pathways on the well-documented
phenomena of cancer dormancy and recurrence. In
particular, in the formulation of the model we considered a generic type of professional antigen presenting cell that was assumed to internalize tumour
cells through either phagocytosis or endocytosis and
display selected tumour antigenic peptides to the effector cells, i.e., the cytotoxic T-lymphocytes (Abbas
et al., 2007).
The dynamics of the model were investigated by
means of numerical simulations, and a number of interesting, counter-intuitive phenomena were discovered. It was demonstrated that, under the assumptions of the model, adoptive immunotherapy protocols have the potential to promote tumour growth
instead of inhibiting it. These results are consistent
with well-documented tumour recurrence phenomena following the application of CTL-based vaccination protocols (Zhang et al., 2007). In contrast, active vaccination with tumour-antigen pulsed APCs
(Banchereau & Palucka, 2005) was shown to be gen-
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erally more effective than adoptive immunotherapy Bellomo, N., Firmani, B. & Guerri, L. (1999), ‘Biprotocols in inhibiting tumour growth and recurfurcation analysis for a nonlinear system of
rence in the model under investigation.
integro-differential equations modelling tumorimmune cells competition’, Appl. Math. Letters
The numerical predictions of our model offer a
12, 39–44.
possible explanation for the uncontrolled behaviour
of a number of lymphocyte vaccine-based therapeutic approaches to certain carcinomas, and our mod- Chaplain, M. & Matzavinos, A. (2006), Mathematical modelling of spatio-temporal phenomelling and analysis offers the potential for quantitaena in tumour immunology, in A. Friedman,
tive analysis of mechanisms of tumour-cell-host-cell
ed., ‘Tutorials in Mathematical Biosciences III:
interactions and for the optimization of immunotherCell Cycle, Proliferation, and Cancer’, Vol.
apy and genetically engineered anti-tumour vaccines.
1872 of Lecture Notes in Mathematics, Springer,
pp. 131–183.
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